Published in J Hepatol on October 25, 2010
Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis (2012) 1.24
Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab (2012) 1.12
Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci U S A (2013) 1.11
Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle (2012) 1.08
Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol (2014) 1.03
Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology (2015) 0.86
Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation. Dig Dis Sci (2013) 0.86
Hyperammonemia results in reduced muscle function independent of muscle mass. Am J Physiol Gastrointest Liver Physiol (2015) 0.84
Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol (2016) 0.81
Changes in nutritional status after liver transplantation. World J Gastroenterol (2014) 0.81
Alteration in body composition in the portacaval anastamosis rat is mediated by increased expression of myostatin. Am J Physiol Gastrointest Liver Physiol (2011) 0.80
Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol (2016) 0.79
Treatment to improve nutrition and functional capacity evaluation in liver transplant candidates. Curr Treat Options Gastroenterol (2014) 0.78
Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology (2017) 0.77
Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. J Physiol (2016) 0.76
Nutrition and Alcoholic Liver Disease: Effects of Alcoholism on Nutrition, Effects of Nutrition on Alcoholic Liver Disease, and Nutritional Therapies for Alcoholic Liver Disease. Clin Liver Dis (2016) 0.75
Skeletal muscle myopenia in mice model of bile duct ligation and carbon tetrachloride-induced liver cirrhosis. Physiol Rep (2017) 0.75
Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle (2015) 0.75
Sarcopenia in alcoholic liver disease: clinical and molecular advances. Alcohol Clin Exp Res (2017) 0.75
Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A (2001) 6.38
A rapid and convenient technique for measuring the rate of protein synthesis in tissues by injection of [3H]phenylalanine. Biochem J (1980) 4.86
Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol (2003) 3.25
The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem (2002) 3.01
Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One (2007) 2.41
The emerging biology of satellite cells and their therapeutic potential. Trends Mol Med (2008) 2.24
Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol (2004) 2.12
Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab (2001) 1.84
Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clin Chem (1982) 1.79
Myofibrillar protein synthesis in myostatin-deficient mice. Am J Physiol Endocrinol Metab (2005) 1.43
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve (2009) 1.34
Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology (1997) 1.24
Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol (2005) 1.16
Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol (2004) 1.13
Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol (2006) 1.02
Expression of the TGF-beta family of ligands is developmentally regulated in skeletal muscle of neonatal rats. Pediatr Res (2006) 1.01
Intravenous administration of follistatin: delivery to the liver and effect on liver regeneration after partial hepatectomy. Hepatology (1996) 0.92
Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Dig Dis Sci (2002) 0.88
Inhibition of aromatase improves nutritional status following portacaval anastomosis in male rats. J Hepatol (2006) 0.85
The role of myostatin in chicken (Gallus domesticus) myogenic satellite cell proliferation and differentiation. Gen Comp Endocrinol (2007) 0.83
Protein synthesis rates in rats with portacaval shunts. J Neurochem (1984) 0.83
Effects of portacaval anastomosis on liver and brain protein synthesis in rats. Surgery (1977) 0.80
Role of serum myostatin during the lactation period. J Reprod Dev (2006) 0.79
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Alcoholic liver disease. Hepatology (2010) 5.04
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem (2002) 4.20
Analysis of the adult human plasma metabolome. Pharmacogenomics (2008) 3.74
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Glyceroneogenesis and the triglyceride/fatty acid cycle. J Biol Chem (2003) 2.60
Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab (2003) 2.56
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr (2009) 2.27
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes (2002) 2.20
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem (2007) 1.85
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology (2006) 1.71
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood) (2002) 1.67
Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3. Endocrinology (2005) 1.59
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
Capsule endoscopy in examination of esophagus for lesions after radiofrequency catheter ablation: a potential tool to select patients with increased risk of complications. J Cardiovasc Electrophysiol (2010) 1.57
What is the metabolic role of phosphoenolpyruvate carboxykinase? J Biol Chem (2009) 1.57
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat. J Biol Chem (2008) 1.49
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis (2002) 1.27
Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the control of hepatic metabolism. Nutr Metab (Lond) (2005) 1.25
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol (2004) 1.23
Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl (2009) 1.22
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
Reassessing triglyceride synthesis in adipose tissue. Trends Endocrinol Metab (2008) 1.18
Measuring protein synthesis using metabolic ²H labeling, high-resolution mass spectrometry, and an algorithm. Anal Biochem (2011) 1.16
Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem (2010) 1.15
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol (2004) 1.13
Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol (2002) 1.12
Overexpression of Dlx5 in chicken calvarial cells accelerates osteoblastic differentiation. J Bone Miner Res (2002) 1.08
Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics (2012) 1.05
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Gender differences in the regulation of amino acid metabolism. J Appl Physiol (1985) (2003) 1.03
Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol (2006) 1.02
Docosahexaenoic acid and arachidonic acid enhance growth with no adverse effects in preterm infants fed formula. J Pediatr (2002) 1.01
Methionine metabolism in human pregnancy. Am J Clin Nutr (2009) 1.01
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol (2013) 1.01
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int (2013) 1.00
Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice. Mol Endocrinol (2004) 1.00
The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem (2008) 0.99
Flawed experimental design reveals the need for guidelines requiring appropriate positive controls in endocrine disruption research. Toxicol Sci (2010) 0.99
The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology (2012) 0.98
Esophageal capsule endoscopy after radiofrequency catheter ablation for atrial fibrillation: documented higher risk of luminal esophageal damage with general anesthesia as compared with conscious sedation. Circ Arrhythm Electrophysiol (2009) 0.97
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. J Biol Chem (2004) 0.95
Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci (2011) 0.94
Localization and action of Dragon (repulsive guidance molecule b), a novel bone morphogenetic protein coreceptor, throughout the reproductive axis. Endocrinology (2005) 0.93
Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis. Obesity (Silver Spring) (2011) 0.93
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus. Diabetes Care (2009) 0.92
Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int (2009) 0.91
The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology (2009) 0.90
Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis (2009) 0.90
Maternal nutrition and optimal infant feeding practices: executive summary. Am J Clin Nutr (2007) 0.90
Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. N Engl J Med (2006) 0.89
A multicenter, prospective, randomized comparison of a novel signal transmission capsule endoscope to an existing capsule endoscope. Gastrointest Endosc (2013) 0.89
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.89
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2013) 0.89
Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism (2010) 0.89
Future trends in hepatology: challenges and opportunities. Hepatology (2008) 0.89
Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol (2014) 0.89
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol (2012) 0.88
Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Dig Dis Sci (2002) 0.88
Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. Metabolism (2008) 0.88
Amino acids, glutamine, and protein metabolism in very low birth weight infants. Pediatr Res (2005) 0.87
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol (2012) 0.87